Abstract
Ischemic stroke is one of the leading causes of mortality and permanent disability in developed countries. Stroke induces massive glutamate release, which in turn causes N-Methyl-D-aspartate (NMDA) receptor over-excitation and thus, calcium overload in neurons leading to cell death via apoptotic cascades. The kynurenine pathway is a complex enzymatic cascade of tryptophan catabolism, generating various neuroactive metabolites. One metabolite, kynurenic acid (KYNA), is a potent endogenous NMDA glutamate receptor antagonist, making it a possible therapeutic tool to decrease excitotoxicity and neuroinflammation. Recently, clinical investigations have shown that during the acute phase of ischemic stroke, kynurenine pathway is activated and peripheral levels of metabolites correlated with worse outcome. In this review, we set out to summarize the current literature on the connection of the kynurenine pathway and ischemic stroke and set a course for future investigations and potential drug development.
Keywords: Kynurenine, stroke, ischemia, immunomodulation, kynurenine analogue, excitotoxicity.
Current Medicinal Chemistry
Title:Ischemic Stroke and Kynurenines: Medicinal Chemistry Aspects
Volume: 25 Issue: 42
Author(s): Péter Hertelendy, József Toldi, Ferenc Fülöp and László Vécsei*
Affiliation:
- Department of Neurology, University of Szeged, Semmelweis u. 6, H-6725 Szeged,Hungary
Keywords: Kynurenine, stroke, ischemia, immunomodulation, kynurenine analogue, excitotoxicity.
Abstract: Ischemic stroke is one of the leading causes of mortality and permanent disability in developed countries. Stroke induces massive glutamate release, which in turn causes N-Methyl-D-aspartate (NMDA) receptor over-excitation and thus, calcium overload in neurons leading to cell death via apoptotic cascades. The kynurenine pathway is a complex enzymatic cascade of tryptophan catabolism, generating various neuroactive metabolites. One metabolite, kynurenic acid (KYNA), is a potent endogenous NMDA glutamate receptor antagonist, making it a possible therapeutic tool to decrease excitotoxicity and neuroinflammation. Recently, clinical investigations have shown that during the acute phase of ischemic stroke, kynurenine pathway is activated and peripheral levels of metabolites correlated with worse outcome. In this review, we set out to summarize the current literature on the connection of the kynurenine pathway and ischemic stroke and set a course for future investigations and potential drug development.
Export Options
About this article
Cite this article as:
Hertelendy Péter, Toldi József, Fülöp Ferenc and Vécsei László *, Ischemic Stroke and Kynurenines: Medicinal Chemistry Aspects, Current Medicinal Chemistry 2018; 25 (42) . https://dx.doi.org/10.2174/0929867325666180313113411
DOI https://dx.doi.org/10.2174/0929867325666180313113411 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intravitreal Bevacizumab for Diabetic Retinopathy
Current Diabetes Reviews Editorial (Thematic Issue: Mitochondrial Biogenesis: Pharmacological Approaches)
Current Pharmaceutical Design Evaluation of Echocardiographic Abnormalities in HIV Positive Patients Treated with Antiretroviral Medications
Infectious Disorders - Drug Targets Methods to Evaluate the Activity of Nitric Oxide Synthase
Current Pharmaceutical Analysis Hyperglycemia and Diabetes Induced by Glucocorticoids in Nondiabetic and Diabetic Patients: Revision of Literature and Personal Considerations
Current Pharmaceutical Biotechnology von Willebrand Factor, von Willebrand Factor-Cleaving Protease, and Shear Stress
Cardiovascular & Hematological Agents in Medicinal Chemistry Prevalence of Neuropsychiatric Symptoms in Alzheimers Disease and Vascular Dementia
Current Alzheimer Research Pharmacological Approaches in the Treatment of Atrial Fibrillation
Current Medicinal Chemistry The p38α Kinase Plays a Central Role In Inflammation
Current Topics in Medicinal Chemistry Netrin-1 in Post-stroke Neuroprotection: Beyond Axon Guidance Cue
Current Neuropharmacology Nitric Oxide Pathway as New Drug Targets for Refractory Hypertension
Current Pharmaceutical Design Misoprostol-induced Acute Coronary Syndrome in a Premenopausal Woman: A Case Report with Literature Review
Current Drug Safety Cerebrovascular and Blood-Brain Barrier Morphology in Spontaneously Hypertensive Rats: Effect of Treatment with Choline Alphoscerate
CNS & Neurological Disorders - Drug Targets The Effect of Lead Exposure on Selected Blood Inflammatory Biomarkers in Guinea pigs
Cardiovascular & Hematological Disorders-Drug Targets Biphasic Mechanisms of Neurovascular Unit Injury and Protection in CNS Diseases
CNS & Neurological Disorders - Drug Targets Enkephalin Degrading Enzymes: Metalloproteases with High Potential for Drug Development
Current Pharmaceutical Design Traditional Chinese Medicine in Treatment of Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets NAD+ Metabolism and NAD+-Dependent Enzymes: Promising Therapeutic Targets for Neurological Diseases
Current Drug Targets Circadian Variation of Cardiovascular Events and Morning Blood Pressure Surge
Vascular Disease Prevention (Discontinued) Tissue Doppler Imaging: Beautiful Noise
Current Cardiology Reviews